Update on Cancer Related Issues of Mesenchymal Stem Cell-Based Therapies
Dechun Wang, Shuguang Wang and Chunmeng Shi
Affiliation: Institute of Combined Injury, State Key Laboratory of Trauma, Burns and Combined Injury, Chongqing Engineering Research Center for Nanomedicine, College of Preventive Medicine, Third Military Medical University, Chongqing 400038, China.
Mesenchymal stem cells (also known as multipotent stromal cells, MSCs) are considered as promising
candidate cells for stem cell-based therapy. However, the applications of MSCs are facing controversial
concerns of potential tumorigenic risks. There is also increasing evidence that MSCs may play a modulatory
role in the development and progression of tumors. MSCs have the potential to migrate to tumor sites and
promote tumor cell proliferation, invasion and metastasis. In addition to these risks, MSCs also have shown to
be an attractive target for gene/cell-mediated anti-tumor therapy. These complicated behaviors of MSCs in cancer
warrant further study to evaluate the benefits of MSCs treatment and the long-term risk of tumor origin or incidence from
MSCs under different pathological conditions.
Keywords: Mesenchymal stem cells (MSCs), malignant transformation, tumor associated fibroblasts (TAF), tumor growth and
metastasis, antitumor therapy, tumorigenic risks, tumor cell proliferation, gene/cell-mediated anti-tumor therapy, Tumor Stromal Cells.
Rights & PermissionsPrintExport